📰 Plus Lenalidomide News
Plus Lenalidomide News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Plus Lenalidomide. Real-time updates on events, politics, business and more.
September 22, 2023
Daratumumab combination is recommended for use within the NHS in England and Wales for treating adults with newly diagnosed multiple myeloma where a stem cell transplant is unsuitableEligible patients throughout England and Wales can now access alternative combination treatment option which has been shown to delay d...
December 12, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...
December 5, 2022
05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...
August 28, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...
August 27, 2022
Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharm
August 27, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...
August 27, 2022
Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen P...
December 11, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...
December 11, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...
December 11, 2021
Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world...